Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “HER-2 Protein Overexpression”

71 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 71 results

Testing effectiveness (Phase 2)UnknownNCT05135715
What this trial is testing

RC48-ADC in Advanced Melanoma Subjects With HER2 Variant (Mutation, Amplification, Overexpression)

Who this might be right for
Melanoma, Stage IIHER2-positiveAdvanced Melanoma
RemeGen Co., Ltd. 50
Testing effectiveness (Phase 2)UnknownNCT05627414
What this trial is testing

Conversion Therapy of Disitamab Vedotin Combined With Sintilimab and S-1 in HER2 Overexpression Gastric Cancer

Who this might be right for
Gastric Cancer
Tianjin Medical University Cancer Institute and Hospital 30
Large-scale testing (Phase 3)Study completedNCT00281658
What this trial is testing

Study In Women And Men With Metastatic Breast Cancer That Have Overexpression Of ErbB2

Who this might be right for
Neoplasms, Breast
Novartis Pharmaceuticals 444
Testing effectiveness (Phase 2)Study completedNCT01036087
What this trial is testing

Panitumumab, Nab-paclitaxel and Carboplatin for HER2 Negative Inflammatory Breast Cancer

Who this might be right for
Breast Cancer
M.D. Anderson Cancer Center 47
Early research (Phase 1)WithdrawnNCT04602117
What this trial is testing

ISPY-P1.01:Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarmazine (SYD985) in Patients With Metastatic Cancer

Who this might be right for
HER2-positive Breast CancerHER2 LowSYD-985+24 more
QuantumLeap Healthcare Collaborative
Testing effectiveness (Phase 2)Study completedNCT00258960
What this trial is testing

Caelyx, Cyclophosphamide and Herceptin in Patients With Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Spanish Breast Cancer Research Group 49
Testing effectiveness (Phase 2)Looking for participantsNCT04879329
What this trial is testing

Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2

Who this might be right for
Urothelial Carcinoma
Seagen, a wholly owned subsidiary of Pfizer 372
Testing effectiveness (Phase 2)WithdrawnNCT05512182
What this trial is testing

Efficacy of Triplet Combination With Pembrolizumab, Neratinib, and Paclitaxel as a Second Line Treatment in Recurrent/Advanced Gastric Cancer Having Somatic Human Epidermal Growth Factor Receptor Family (EGFR, HER2, HER3, HER4) Mutations or HER2 Amplification/Overexpression

Who this might be right for
Recurrent/Advanced Gastric Cancer
Yonsei University
Testing effectiveness (Phase 2)Study completedNCT03556345
What this trial is testing

RC48-ADC in Local Advanced or Metastatic Gastric Cancer Subjects With the Overexpression of HER2

Who this might be right for
Gastric CancerHER2 Overexpressing Gastric Carcinoma
RemeGen Co., Ltd. 127
Testing effectiveness (Phase 2)Study completedNCT00401427
What this trial is testing

HERVIN: Trastuzumab and Vinorelbine in Metastatic Breast Cancer

Who this might be right for
Metastatic Breast Cancer
National Cancer Institute, Naples 50
Early research (Phase 1)Ended earlyNCT03680560
What this trial is testing

Study of ACTR T Cell Product in Combination With Trastuzumab in Subjects With HER2-Positive Advanced Solid Tumor Cancers

Who this might be right for
Solid TumorHER-2 Protein Overexpression
Cogent Biosciences, Inc. 6
Early research (Phase 1)Looking for participantsNCT04995003
What this trial is testing

HER2 Chimeric Antigen Receptor (CAR) T Cells in Combination With Checkpoint Blockade in Patients With Advanced Sarcoma

Who this might be right for
SarcomaHER-2 Protein OverexpressionOsteosarcoma+5 more
Baylor College of Medicine 25
Not applicableActive Not RecruitingNCT02295059
What this trial is testing

Omega 3 Fatty Acids and ERPR(-)HER2(+/-) Breast Cancer Prevention

Who this might be right for
Breast Cancer
City of Hope Medical Center 80
Very early researchWithdrawnNCT02735798
What this trial is testing

64-Cu Labeled Brain PET/MRI for MM-302 in Advanced HER2+ Cancers With Brain Mets

Who this might be right for
Brain MetastasesDocumented Her2 OverexpressionAdvanced Solid Tumor+1 more
Pamela Munster
Testing effectiveness (Phase 2)Study completedNCT00033514
What this trial is testing

Trastuzumab and Erlotinib as First-Line Therapy in Treating Women With Metastatic Breast Cancer Associated With HER2/Neu Overexpression

Who this might be right for
Breast Cancer
Jonsson Comprehensive Cancer Center 27
Testing effectiveness (Phase 2)WithdrawnNCT04464967
What this trial is testing

Safety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in Subjects With Advanced HER2 or EGFR Cancers

Who this might be right for
Advanced Solid TumorMetastatic CancerHER2-positive Breast Cancer+14 more
NKGen Biotech, Inc.
Early research (Phase 1)Study completedNCT00009997
What this trial is testing

Trastuzumab and Chemotherapy Followed by Surgery and Combination Chemotherapy in Treating Women With Locally Advanced Breast Cancer

Who this might be right for
Breast Cancer
NYU Langone Health
Not applicableUnknownNCT02136836
What this trial is testing

Investigation of the Proportion of Human Epidermal Growth Factor Receptor 2 Protein Overexpression of Gastric Adenocarcinoma and Prognostic Effect of HER2, and Analysis of Practice Pattern of Herceptin Use in Stage IV Gastric Cancer

Who this might be right for
Stomach Neoplasms
Yonsei University 860
Early research (Phase 1)Study completedNCT00014430
What this trial is testing

Chemotherapy Plus Trastuzumab in Treating Patients With Breast Cancer

Who this might be right for
Breast Cancer
Dartmouth-Hitchcock Medical Center 13
Testing effectiveness (Phase 2)Looking for participantsNCT06187506
What this trial is testing

Disitamab Vedotin Combined With BCG Therapy in HER2-expressing High-risk Non-muscle Invasive Bladder Cancer

Who this might be right for
Non-muscle Invasive Bladder CancerHER-2 Protein Overexpression
Fudan University 20
Load More Results